Allergic Rhinitis Drugs Market Report 2025

This Allergic Rhinitis Drugs market report provides a comprehensive analysis of the market’s characteristics, size, and growth, including segmentation, regional and country-level breakdowns, competitive landscape, market shares, trends, and strategies. It also tracks historical and forecasted market growth across various geographies.

The allergic rhinitis drugs market size has grown steadily in recent years. It will grow from $15.67 billion in 2024 to $16.42 billion in 2025 at a compound annual growth rate (CAGR) of 4.8%. The growth in the historic period can be attributed to rising awareness about allergic reactions and available treatment modes, increasing prevalence of allergic rhinitis, heightened demand for effective drugs, and the popularity of over-the-counter (OTC) allergy medications.

The allergic rhinitis drugs market size is expected to see steady growth in the next few years. It will grow to $19.61 billion in 2029 at a compound annual growth rate (CAGR) of 4.5%. The growth in the forecast period can be attributed to growing pollution levels coupled with a rise in respiratory disorders, increasing environmental pollution, changing climatic conditions, a rise in the number of individuals suffering from allergies, and rising awareness about allergic reactions and available treatment modes. Major trends in the forecast period include technological developments in treatment methods, the development of new antihistamines, technological advances in allergy rhinitis diagnostics, advancements in the field of allergy treatment, increase in research and development of new therapies.

The increasing incidence of respiratory disorders is expected to drive the growth of the allergic rhinitis drug market. Respiratory disorders include a variety of conditions that impact the lungs and airways. This rise is largely attributed to greater exposure to environmental pollutants, such as air pollution and allergens, along with climate change and a higher prevalence of respiratory infections. Allergic rhinitis drugs are crucial for managing these disorders, as they reduce inflammation and alleviate symptoms such as nasal congestion and sneezing, thus improving respiratory function. For example, in April 2024, the Centers for Disease Control and Prevention, a US-based governmental body, reported that the percentage of adults with current asthma increased from 8% in 2021 to 8.9% in 2023. Consequently, the growing prevalence of respiratory disorders is fueling the growth of the allergic rhinitis drug market.

Leading companies in the Allergic Rhinitis Drugs market are focusing on developing innovative solutions, such as novel probiotics, to effectively enhance immune responses and alleviate allergy symptoms. These novel probiotics are being studied for their potential to regulate the immune system and reduce symptoms of allergic rhinitis. By supporting a balanced gut microbiome, they present a promising natural alternative to conventional treatments. For example, in March 2024, Entod Pharma, a pharmaceutical company based in India, introduced Lactoshield RH for managing nasal allergies, including allergic rhinitis. This product features clinically tested probiotic strains designed to stabilize gut flora and modulate immune responses, potentially easing symptoms of nasal allergies.

In January 2022, Glenmark Pharmaceuticals Limited formed a partnership with Lotus Pharmaceutical Co. Ltd. to extend the market reach of Ryaltris into Singapore, Hong Kong, and Vietnam. This collaboration allows Glenmark to utilize Lotus's established network in Southeast Asia for the introduction of Ryaltris, while Lotus will manage commercialization, pending regulatory approvals to ensure compliance and facilitate market entry. Lotus Pharmaceutical Co. Ltd. is a Taiwan-based pharmaceutical company.

Major companies operating in the allergic rhinitis drugs market are Pfizer Inc., Johnson & Johnson, Merck & Co., Bayer AG, Sanofi SA, AstraZeneca plc, Novartis AG, GlaxoSmithKline PLC, Boehringer Ingelheim International GmbH, Viatris Inc., Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Bausch Health Companies Inc., Sun Pharmaceuticals Industries Ltd., Perrigo Company plc, Dr. Reddy’s Laboratories, Apotex Inc., Meda AB, Amneal Pharmaceuticals Inc., Glenmark Pharmaceuticals Ltd, ALK-Abelló A/S, Stallergenes Greer plc, Himalaya Wellness Company, Unichem Laboratories Limited, Aytu BioPharma Inc., Allergy Therapeutics PLC, DMK Pharmaceuticals Corporation, Revolo Biotherapeutics.

Asia-Pacific was the largest region in the allergic rhinitis drugs market in 2024. The regions covered in the allergic rhinitis drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the allergic rhinitis drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Allergic rhinitis drugs are medications used to alleviate symptoms of allergic rhinitis, a condition marked by inflammation of the nasal passages due to allergens such as pollen, dust, mold, or animal dander. These drugs help relieve symptoms such as sneezing, itching, nasal congestion, and a runny nose.

The main types of allergic rhinitis covered by these drugs include seasonal allergic rhinitis, perennial allergic rhinitis, and occupational allergic rhinitis. Seasonal allergic rhinitis, often referred to as hay fever, occurs at specific times of the year when allergens such as pollen from trees, grasses, or weeds are prevalent. Treatments for allergic rhinitis include antihistamines, immunotherapy, corticosteroids, decongestants, and other medications. These treatments can be administered through various routes, including oral, nasal, intraocular, and intravenous methods. They are distributed through channels such as retail pharmacies, hospital pharmacies, and online platforms.

The allergic rhinitis drugs market research report is one of a series of new reports that provides allergic rhinitis drugs market statistics, including allergic rhinitis drugs industry global market size, regional shares, competitors with an allergic rhinitis drugs market share, detailed allergic rhinitis drugs market segments, market trends, and opportunities, and any further data you may need to thrive in the allergic rhinitis drugs industry. This allergic rhinitis drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The allergic rhinitis drugs market consists of sales of mast cell stabilizers, drops, and saline nasal sprays. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.